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Abstract
Background: Various interventions have been tested to achieve adherence to anti-psychotic
maintenance medication in non-adherent patients with psychotic disorders, and there is no
consistent evidence for the effectiveness of any established intervention. The effectiveness of
financial incentives in improving adherence to a range of treatments has been demonstrated; no
randomised controlled trial however has tested the use of financial incentives to achieve
medication adherence for patients with psychotic disorders living in the community.
Methods/Design: In a cluster randomised controlled trial, 34 mental health teams caring for
difficult to engage patients in the community will be randomly allocated to either the intervention
group, where patients will be offered a financial incentive for each anti-psychotic depot medication
they receive over a 12 month period, or the control group, where all patients will receive
treatment as usual. We will recruit 136 patients with psychotic disorders who use these services
and who have problems adhering to antipsychotic depot medication, although all conventional
methods to achieve adherence have been tried. The primary outcome will be adherence levels, and
secondary outcomes are global clinical improvement, number of voluntary and involuntary hospital
admissions, number of attempted and completed suicides, incidents of physical violence, number of
police arrests, number of days spent in work/training/education, subjective quality of life and
satisfaction with medication. We will also establish the cost effectiveness of offering financial
incentives.
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BMC Psychiatry 2009, 9:61 http://www.biomedcentral.com/1471-244X/9/61Discussion: The study aims to provide new evidence on the effectiveness and cost effectiveness
of offering financial incentives to patients with psychotic disorders to adhere to antipsychotic
maintenance medication. If financial incentives improve adherence and lead to better health and
social outcomes, they may be recommended as one option to improve the treatment of non-
adherent patients with psychotic disorders.
Trial Registration: Current controlled trials ISRCTN77769281.
Background
Various clinical interventions have been tested to achieve
adherence in non-adherent patients with psychotic disor-
ders, including compliance therapy, psychotherapy, fam-
ily education, telephone prompting and psycho
education. A review focusing on studies involving patients
with chronic health problems [1] and a meta-analysis of
studies to enhance adherence in psychiatric patients [2]
found a modest effect of some interventions (effect size of
.36 in psychiatric patients). Yet, there is no consistent evi-
dence for any intervention to significantly improve medi-
cation adherence in non-adherent community patients
with psychotic disorders.
Guiffrida and Togerson, 1997 [3] conducted a systematic
review on financial incentives to increase adherence to
health care treatments. They identified 11 randomised
controlled trials, all from the USA. In 10 studies financial
incentives enhanced adherence to anti-tuberculosis drugs,
dental care, a weight reduction programme, substance
dependency treatment, and anti hypertensive medication
with odds ratios of up to 7 for anti-tuberculosis treatment.
Only one study in the review addressed a mental health
issue, i.e. adherence to cocaine dependency treatment.
One non-randomised study of patients with dual diagno-
sis found that modest rewards enhanced attendance to the
programme [4].
Since there is no published review specifically on studies
in patients with mental health problems, we conducted
our own review. The following databases were searched
for studies: AMED, EBM, EMBASE, MEDLINE and Psy-
cINFO. The following keywords were combined simulta-
neously to identify studies: medication, therapy,
appointment, compliance, adherence, mental health,
mental illness and psychiatr, with the terms incentive,
compliance, money, payment, contingency management,
voucher and material. We found 13 USA based studies [4-
16] where incentives have been used to encourage adher-
ence to treatment in people with mental health problems,
10 of which included people with substance misuse and
mental health problems. One study was carried out in the
UK [17]. Treatment included attendance of therapeutic
sessions and out-patient clinics, and abstinence from
smoking or substance abuse. Incentives offered were in
the form of a direct payment of vouchers, money or
tokens. Nine out of the fourteen studies were within-sub-
jects designs and four studies were controlled trials. Two
controlled trials examined the effect of offering incentives
to promote abstinence from substances, one studied
active involvement in inpatient group meetings and one
combined attendance at compensated work therapy and
abstinence from substances. In all of the studies, the indi-
viduals' adherence/abstinence was significantly improved
when incentives were offered. In half of the studies, the
improvement in outcome was maintained even when the
incentive had been taken away. None of these studies
referred to any problems or concerns raised in offering
incentives. Yet, we did not find a single controlled study
testing financial incentives to improve medication adher-
ence in patients with mental health disorders.
A recent publication from the UK reported the use of
financial incentives in non-adherent patients in Assertive
Outreach Teams (AOTs) [17]. Four out of 5 patients who
were offered the scheme accepted. All had improved
adherence to medication and three remained without
hospital admissions throughout the observation period
although they had been frequently admitted before the
scheme. No wider research has so far been published.
The use of financial incentives to increase adherence to
anti-psychotic medication also raises ethical concerns as
shown in a survey of AOT managers in England [18]. A
recent study (Priebe et al, in preparation) explored the
views and attitudes of different stakeholder groups related
to the use of financial incentives in mental health care.
Practically all stakeholder groups identified the issue of
effectiveness as critical for their view of the intervention
and asked for systematic research to establish its effective-
ness.
A clinical trial on the effectiveness of financial incentives
will inform the ethical debate on the principle of provid-
ing such an intervention [18]. One of four categories for
judging the ethical dimension of medical interventions is
their beneficence [19]. Beneficence is closely linked to
effectiveness, and identifying effectiveness requires a ran-
domised controlled trial. Although there may be various
indications that financial incentives are likely to increasePage 2 of 9
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previously non-adherent patients, the effectiveness and
cost-effectiveness of the intervention has never been
established in a randomised design, and a randomised
controlled trial is required before the wider use of the
intervention should be recommended.
Methods
Design
In a cluster randomised controlled trial, community
teams caring for patients with psychotic disorders in the
community, currently AOTs, will be randomly allocated
to the intervention group or control condition. The allo-
cation of teams, and not individual patients, will prevent
contamination of practice within teams and facilitate the
assessment of overall experiences in teams with the prac-
tice. It will also make it possible for teams in the experi-
mental group to offer financial incentives to further
patients outside the study, without compromising the
study design. Teams might consider this to avoid a sense
of unfairness among patients cared for by the same team
or simply to have more patients benefiting from the inter-
vention. Outcomes will be analysed on the level of indi-
vidual patients. The effect of clustering of patients within
teams will be controlled for in a mixed effects model. The
trial will not be 'blind', as masking of patients and clini-
cians is impossible. Yet, the primary outcome criterion
(percentage of injections taken) and secondary outcomes,
with the exceptions of global clinical improvement which
is rated by clinicians and subjective quality of life and
treatment satisfaction which is rated by patients, can be
obtained objectively and are taken from the medical
records, and should therefore not be influenced by lack of
masking.
AOTs will first be approached and informed about the
study through the National Forum for Assertive Outreach
and local collaborators at study centres in London,
Oxford and Liverpool. We will approach around 100
AOTs that are based within reasonable distance of the
study sites so that regular travelling to the teams is realis-
tic. AOTs will receive information about the study on
regional and national meetings of AOTs and material cir-
culated through email. This will be followed up by direct
telephone calls of the director of the National Forum for
Assertive Outreach and other members of the research
team including the research assistants. Although we
expect that a number of teams will object to either the
practice of offering financial incentives or being randomly
allocated within a research design or both, informal con-
sultations showed that we can expect more than 36 teams
to volunteer for participation in the study. To include an
AOT in the pool of eligible teams we will ask for prelimi-
nary informed consent by the team manager. AOTs
already practising a financial incentive scheme will be
excluded. Yet, a survey conducted in 2006 [18] identified
only one AOT in England using financial incentives at the
time, and this number is unlikely to have increased sub-
stantially since. We will then randomly select 36 teams
out of the pool of volunteering teams, allowing for two
teams to drop out in the further procedure before the trial
begins.
All recruited teams will be visited by a member of the
research team to explain the nature of the intervention
and the study. Clinicians and managers in all teams will
receive a structured presentation addressing the research
background, the design of the trial, and ethical as well as
practical issues of implementation. Written informed con-
sent to participate will then be obtained from team man-
agers and psychiatrist consultants.
The next step will be to identify patients in each team ful-
filling the inclusion criteria. We expect the number of
patients in most teams to vary between 5 and 8. We expect
to recruit 4 patients per team and will randomly select
patients if required. These patients will be informed about
the study by a clinician and then approached by a
researcher for written informed consent for their data to
be used in research and for participating in a trial, in
which patients in some but not all teams are offered finan-
cial incentives to improve medication adherence. If
patients cannot be contacted initially or do not provide
written informed consent, further patients fulfilling the
inclusion criteria will be recruited from the participating
teams until the total sample size is reached. Selecting and
recruiting patients before randomisation is essential to
avoid a possible bias in the selection and recruitment pro-
cedures based on awareness of whether patients will be in
the experimental or control group. After this one-off con-
tact between the patient and a research assistant, there will
be no requirement for further contacts between research
assistants and patients in either group. Following the ini-
tial interview, patients are not required to participate in
any research interviews or assessments at any point of
time. This simple and non-intrusive procedure is meant to
minimise the number of non-consenting patients (which
always is a problem with research in challenging patients
in AOTs) and avoid a selection bias as far as possible.
Only if patients volunteer to be contacted at the end of the
trial again, a researcher will attempt such contact (possi-
bly via telephone) to ask 11 questions on patient reported
outcomes.
After the recruitment of patients, 34 AOTs will be ran-
domly allocated to the intervention or control condition
stratifying for the type of catchment area (i.e. inner city,
suburban or rural).Page 3 of 9
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Patients in the AOTs that have been allocated to the inter-
vention will be offered a financial incentive for each depot
injection of anti-psychotic medication for a 12 month
period. Patients will receive £15 for one injection with the
total sum not exceeding £60 for a four-week period (the
maximum number of injections is 4 per month). The
administering clinician will give the money in cash
directly after the injection. Patients will sign a receipt.
There are several reasons to set a standard sum of £15 for
each depot injection:
• A fixed sum per injection simplifies the practice and
makes it transparent for all clinicians and patients
involved.
• The sum of £15 is in line with the successful open pilot
study in East London.
• The sum is below the limit of £20 per week which would
interfere with patients' disability benefits. Most patients
eligible for the study receive Disability Living Allowance,
Income Support with Disability Premium, or Incapacity
Benefit. In all of these cases, patients are not entitled to
have a separate income of more than £20 (including ther-
apeutic earnings and income through research participa-
tion) without having their benefits reduced.
• £15 per injection is intended to be an incentive helping
persuade otherwise ambivalent patients. Yet, it is impor-
tant to limit the total sum to a maximum of £60 per four
weeks so that patients do not become financially depend-
ent on the additional income. The money is intended to
provide an incentive, but not lead to financial dependence
on the scheme.
Otherwise all patients will receive treatment as usual. The
type, frequency and dosage medication and all other
interventions will not be affected by participation in the
study.
Members of the research team will attend meetings of
each AOT in the intervention group and discuss again the
practice of offering financial incentives and the nature of
the study. Following that there will be a brief training pro-
gramme on the exact procedure. The procedure of the
intervention will also be outlined in a written manual. All
teams will then be regularly visited by the research assist-
ants and, if required, also by members of the team of
applicants. A discussion of the practice at a team meeting
will be repeated after 6 months of the intervention period.
Inclusion criteria
The only inclusion criterion for teams is that they care for
patients with psychotic disorders who have problems
adhering to antipsychotic maintenance medication. These
are currently dedicated AOTs with a corresponding policy.
The only exclusion criteria are lack of willingness to par-
ticipate and an already existing practice of offering finan-
cial incentives to patients with problematic medication
adherence.
For patients in the AOTs there are the following inclusion
criteria:
• being cared for in the AOT for at least 4 months,
• between 18 and 65 years of age,
• capacity to give informed consent to participate in the
study and actual written informed consent,
• an established diagnosis of schizophrenia, schizo-affec-
tive psychosis, or bipolar illness according to ICD-10,
• being prescribed depot injections of anti-psychotic med-
ication,
• poor adherence to anti-psychotic medication, i.e. missed
50% or more of prescribed depot injections over the last 4
months (so that the percentage of taken depots is based
on a minimum of 4 prescribed depots), and
• failure of all other methods available to the team to
ensure adherence to medication.
Exclusion criteria
Exclusion criteria are:
• learning difficulty
• poor command of English so that clinical communica-
tion and discussion of agreements is impaired
Outcome measures
The primary outcome is adherence to anti-psychotic
maintenance medication during the 12 month trial
period. Adherence will be measured, objectively, as the
percentage of prescribed depot injections actually taken.
As the primary outcome, the percentage will be used as a
continuous variable. However, we will also analyse the
percentage in a dichotomised way, comparing the ratio of
patients with 'good' adherence (i.e. =80% of prescribed
depots taken [20]) in the two conditions.
Further secondary outcomes are:
a) The time 'slippage' of taking depots, defined as the per-
centage of the prescribed time interval that has expired
before the depot is taken;Page 4 of 9
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bal Impression Scale (CGI) [21] by the treating consultant
psychiatrist at the end of the 12 month period;
b) Number of involuntary and voluntary hospital admis-
sions during the trial period;
c) Costs of care: data on the use and frequency of use of
inpatient care, outpatient care (including home visits,
home treatment), and other health services during the 12
month treatment period will be obtained from case notes
and electronic administrative data bases. Costs for the
intervention will be estimated for each participating team
from information provided by staff. Established national
unit costs will be used to estimate direct health care.
d) The number of attempted and completed suicides, inci-
dences of physical violence, police arrests and days spent
at work/training/education will also be recorded over the
12 month trial period.
e) Subjective quality of life and satisfaction with medica-
tion which will be assessed at the beginning and end of
the intervention period using the 11 item scale estab-
lished in the DIALOG trial [22]. The scale contains 11
items asking patients to rate their satisfaction with 8 life
domains and 3 treatment aspects, one of which is medica-
tion, on a scale ranging from 1 (lowest satisfaction) to 7
(highest satisfaction).
f) Continuation with financial incentives (in intervention
group only) and adherence during a 6 month follow up
period will be taken from the medical records.
g) Teams in the intervention group will be asked after 6
months, 12 months and 18 months about all aspects of
experiences with the scheme including whether patients
on the scheme asked for an increase of the incentive, and
whether other patients with hitherto good adherence also
asked for financial incentives and/or became poorly
adherent in order to be eligible for the incentives. This will
be done using open questions with a written documenta-
tion of the answers.
Simple measures of subjective quality of life and satisfac-
tion with medication are the only patient reported out-
come criteria used in the study. They have been included
to obtain a subjective outcome that reflects the user per-
spective. However, this will be an element that patients
can participate in or not. If they do not consent to be con-
tacted for completing the scale at the end of the interven-
tion period, they will still participate in the trial, and there
are no mandatory patient rated or interview based criteria.
The patients to be recruited for the trial have been 'diffi-
cult to engage' in care, and many may refuse participating
because they do not want to be interviewed by a
researcher or complete questionnaires. This would result
in difficulties to recruit and - more importantly - a signifi-
cant selection bias.
Risks and anticipated benefits for trial participants and 
society including how benefits justify risks
There are potential risks linked to offering financial incen-
tives for patients in the intervention group. These include
that patients a) become financially dependent on the
incentive, b) demand more money over time, c) will not
want to terminate the scheme although they might be pre-
pared to adhere to medication even without the incentive,
and d) spend the additional income on illegal drugs. Also,
other patients who have been adherent so far might ask to
be offered financial incentives as well and/or decrease
their adherence to become eligible. Based on 5 years expe-
rience with the intervention in the AOT in the East Lon-
don Borough of Newham, one can expect most of these
risks to be limited. No patient with good adherence has
ever asked to receive financial incentives as well (and to
our knowledge none has ever become poorly adherent in
order to be eligible for the scheme). One patient receiving
the intervention has once asked for the money to be
increased which was declined without any negative conse-
quences. The financial dependence is difficult to judge,
but the maximum overall amount of £60 per 4 week
period is rather small to induce dependence. We cannot
guarantee whether patients spend the additional income
on illegal drugs, but all patients have civil rights and the
capacity to decide on what they want to spend their
money and, on a practical level, the amount of incentives
is not sufficient to fund a significant use of illegal drugs.
The anticipated benefits for the patient include a much
better quality of life with reduced distress, lower suicide
risk, fewer problems with the justice system, lower rate of
compulsory treatment and less time spent in psychiatric
in-patient units. Some patients may see the benefit of the
medication, change their attitude towards it and later take
it without financial incentives [23].
The potential benefits to society include a reduced risk of
patients to harm others and much lower costs in terms of
input of health services and other services in the society
including the police and the justice system.
For patients in the control group there are no discernible
risks or benefits. They will only be asked whether they
consent to their data being used for research and would
consider in principle an offer of financial incentives to
take their medication. Their care will not be altered at all.
For patients in either group there are a maximum of
eleven satisfaction ratings on one scale, but no potentially
distressing interviews or assessments. In the interventionPage 5 of 9
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refuse further financial incentives and medication itself at
any point of time.
Trial Steering Committee and Data Monitoring 
Committee
A trial steering committee (TSC) will be established with
an independent chair, a user representative, and at least
two further independent experts.
Although the amount of data collection is limited in the
trial, we will also establish a Data Monitoring and Ethics
Committee (DMEC) because of the ethically sensitive
nature of the intervention. The DMEC will be independ-
ent of the applicants and report to the TSC. It is suggested
to have a joint TSC/DMEC meeting at the beginning of the
study, and subsequently arrange DMEC meetings before
the TSC meetings. The meetings of both groups will be
scheduled for times immediately following the expected
delivery of major milestones, i.e. in month 6, 12 and 25
of the study
Ethical approval
The study has been approved by Ealing and West London
Research Ethics Committee (REC reference number: 09/
H0710/35). All data will be anonymised and stored
securely in line with the Data Protection Act. No pub-
lished data will contain patient identifiable information.
Statistical analysis
For analysis, we will use generalized linear models as
appropriate to the outcome, with random effects for
groups, and sensitivity analyses to explore the impact for
missing data. A detailed Statistical Analysis Plan will be
agreed by the TSC prior to analysis of un-blinded data.
Economic analysis
A cost-effectiveness analysis will be conducted from an
NHS perspective, using data on health service use,
national unit cost figures and the main outcomes in turn
(adherence, time 'slippage' of taking depots, CGI). Incre-
mental cost-effectiveness ratios and cost-effectiveness
acceptability curves will be estimated and employed as
necessary, generated from the net benefit approach and
using bootstrap regression for a range of values of willing-
ness to pay for incremental outcome changes. Sensitivity
analyses will examine the impact of altering key assump-
tions and parameter values. It is usual in any trial to find
differences in service access, treatment adherence, base-
line characteristics, changes in outcome dimensions over
time, cost and cost-effectiveness. In the present study,
these variations would be of particular interest, and we
therefore plan to analyse patterns within the samples in
order to examine whether there are identifiable patterns of
inequity with respect to need, socioeconomic group, and
key demographic characteristics. The concentration index
approach, now quite widely used in health economics for
example, offers a robust and informative methodology
[24].
Proposed sample size
We will recruit 34 AOTs in England (initially 36 to allow
for two teams to drop out between recruitment and begin-
ning of trial), and 4 patients within each team. Seventeen
teams each will be randomly allocated to the experimen-
tal group and the control intervention, i.e. 'treatment as
usual'. We aim to have 68 patients in each arm of the trial,
allowing for one patient per team to be lost between
recruitment and one year follow up. This estimate of a loss
of one patient per team may be rather pessimistic, but
enables us to have a minimum of 52 patients per arm
(assuming that in at least one team per arm there will be
no loss to follow up) included in the intention-to-treat
analysis. Dropping out of the study and the intention-to-
treat analysis will occur only because of a) death, b) long-
term imprisonment, c) long-term hospitalisation, d)
unknown whereabouts with no chance to obtain outcome
data, or e) withdrawal of consent for the data to be used
for research. Patients in the intervention group may dis-
continue with the intervention within the one year study
period, because their clinicians think that maintenance
medication is not appropriate anymore or patients them-
selves decide to come off the scheme. Such patients will
still be included in the intention to treat analysis, and dis-
continuing with the scheme will not compromise the
availability of outcome data. Refer to Figure 1. CONSORT
Flow Diagram for details.
According to the definition of good adherence as taking at
least 80% of prescribed medication, the study is powered
to detect a difference in adherence from 25% in the TAU
arm to 65% in the experimental arm with 90% power for
5% significance. To convert this to a continuous measure
requires an estimate of the standard deviation of the per-
centage of medication taken: Remington et al 2007 [20]
estimate this as 31%. This estimate may appear high,
which makes our power calculation rather conservative.
Assuming the 31% standard deviation pertains to both
arms, the original assumptions are then equivalent to
assumed means of 60% of prescribed medicine on TAU,
and 92% on treatment. In fact, the mean in Remington et
al [20] was 66%, so the revised sample size calculations
on the continuous measure are powered for a more mod-
est increase from 65% to 85% (an absolute difference of
20%). This would require 47 per group in an individually
randomised study. This then has to be inflated to allow for
clustering. Assuming an ICC of 0.05 and an average of 3
patients per team gives an inflation factor of 1.1 [25] or 52Page 6 of 9
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This figure displays the CONSORT Flow Diagram.
Excluded
64 AOTs not consenting to 
participate or already using 
financial incentives 
Allocated to intervention: M4M 
17 AOTs, 68 participants
average cluster size = 4 
Approached for  par ticipation:
100 Assertive Outreach Teams (AOTs) 
Enrollment Teams 
36 AOTs 
Allocated to control condition 
17 AOTs, 68 participants
average cluster size = 4 
Randomisation at cluster  level:  
34 AOTs with 4 patients each 
Assessed for  eligibility and potentially 
approached for  recruitment:
ca. 240 patients to achieve recruitment 
of 4 patients per AOT 
Excluded
Ca. 96 participants who  
cannot be contacted, do not meet 
inclusion criteria or do not 
provide informed consent 
Drop out    
2 AOTs with 4 patients each, 
withdrawing consent to 
participate 
Recruited to study:
144 Participants – 4 patients per AOT 
        Allocation
Lost to one year  follow-up: 
 0 AOT 
16 participants  
Possible reasons of individual 
loss to follow up:     
Long term hospitalisation 
Long term imprisonment 
Community treatment order 
Unknown whereabouts 
Withdrawal of consent 
Death
Lost to one year  follow-up: 
 0 AOT 
16 participants  
Possible reasons of individual 
loss to follow up:     
Long term hospitalisation 
Long term imprisonment 
Community treatment order 
Unknown whereabouts 
Withdrawal of consent 
Death
One year  follow-up 
Clusters analysed: 
17 AOTs 
Par ticipants analysed:  
52 patients 
Clusters analysed: 
17 AOTs 
Par ticipants analysed:  
52 patients 
Analysis 
25
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up data from at least 3 patients each from 17 teams per
arm (and for 4 patients in one team in each arm). To allow
for potential dropout we will actually recruit 4 per team.
We do not propose a correction for variable group size.
The numbers recruited per team are under our control and
the loss to follow-up rate is likely to be low with small dif-
ferences between teams. Thus, the coefficient of variation
of the group sizes is unlikely to exceed 23% [26].
Discussion
The trial aims to establish the effectiveness and cost effec-
tiveness of offering financial incentives to improve adher-
ence to antipsychotic maintenance medication. The target
group are patients with psychotic disorders who do not
adhere to medication, although they are likely to benefit
from it. The primary outcome is adherence to medication.
We assume that an improved adherence to medication
will be associated with significant health and social gains
for the patients concerned. However, the aim of this trial
is only to test an intervention to improve adherence and
not whether antipsychotic maintenance medication is
indeed effective or not. We therefore decided to use health
and social outcomes only as secondary criteria, although
improving them is the ultimate objective of the whole
intervention.
It would also have been desirable to have patient reported
measures, e.g. on their attitude to treatment in general and
to medication in particular, as a central outcome. How-
ever, the target group of this study are very difficult to
engage in care and often even more difficult to engage in
research trials. Requiring patients to attend interviews or
fill in questionnaires may have limited recruitment and
lead to substantial drop out rates. Thus, the ideal research
design cannot be implemented because patients are likely
not to comply.
We plan to conduct the study with and in AOTs. Yet, given
the possible organisational changes in the NHS which can
be difficult to anticipate, we may have to deal with teams
that are re-configured during the duration of the trial. The
research team will try and implement the study protocol
despite such changes. We will aim to ensure that the allo-
cation of patients to teams in the experimental arm or
control group throughout the study period is not compro-
mised. This may be a challenge since the research team
has no managerial or clinical control over the participat-
ing clinical teams. We will also aim to assess the general
experiences of teams with the practice, e.g. whether other
hitherto adherent patients also asked for financial incen-
tives and whether teams continue with offering financial
incentives to the study patients after the end of the trial.
These general experiences may be highly relevant for a
potential wider implementation of the intervention.
If the trial shows that offering financial incentives is effec-
tive and cost-effective, it may be recommended as an
option in the treatment of patients with psychotic disor-
ders who are non-adherent to medication. The measure is
not coercive and requires patients to have full capacity to
make the decision to both taking the medication and
accepting a financial incentive. There is no reliable data on
the exact size of that group of patients. One may estimate
that between 1000 and a maximum of 5000 patients in
the UK may fall into this category at one point of time.
However, the implications of a positive finding may go
beyond the UK and also affect treatment of similar
patients in other countries.
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